Regeneron begins coronavirus antibody cocktail late-stage trial
A technician at Regeneron Prescribed drugs headquarters in Tarrytown, New York.
Mike Segar | Reuters
Regeneron Pharmaceuticals said on Monday it started late-stage scientific trials to assess the effectiveness of its antibody cocktail in blocking and treating Covid-19.
The trial, operate jointly with the National Institute of Allergy and Infectious Illnesses, would take a look at the therapy’s potential to prevent an infection in these who have experienced close publicity to a Covid-19 client.